Sagimet Biosciences is a clinical-stage biopharmaceutical company developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Co.'s primary drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). Co. is testing denifanstat in its FASCINATE-2 Phase 2b clinical trial in NASH. Co. is also evaluating the promise of FASN inhibition in other disease areas in which dysregulation of fatty acid metabolism also plays a role, including in acne and certain forms of cancer. The SGMT average annual return since 2023 is shown above.
The Average Annual Return on the SGMT average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SGMT average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SGMT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|